Biotechnology stocks worldwide, ranked

As of 13 Nov 2026, Harmony Biosciences Holdings (HRMY) ranks first in Biotechnology on MoatMap, with a MoatMap Score of 99/100, among 478 companies in 22 countries worth $200M or more that trade $1M or more a day. A research ranking, not investment advice.

The score reads each company's latest yearly results, so when a whole industry is near the top of its cycle, its companies can rank high together.

Live list, follows each night's scores · scores as of ·How we score stocks

The top 25 Biotechnology companies by MoatMap Score

#StockYieldP/EScoreQVMStyle · Activity
1
HRMY
Harmony Biosciences Holdings, Inc.
United States · $2.1B

Quality 80: strong free cash flow and ROIC in the top 5% of its sector. Value 76: cheap on free cash flow and cheap on EV/EBITDA. Momentum 66: above its moving averages and EPS improving.

Yield —P/E 11.0
99
Score
80
Q
76
V
66
M
Full HouseDir. sell $3.1MDeep dive →
2
PLX
Protalix BioTherapeutics, Inc.
United States · $205.5M

Momentum 82: quarterly earnings growing and outperforming the market over 6 months. Quality 75: ROIC in the top 5% of its sector and high return on equity. Value 66: cheap on P/E and cheap on EV/EBITDA.

Yield —P/E 11.0
99
Score
75
Q
66
V
82
M
Full House
3
BAVA.CO
Bavarian Nordic A/S
Denmark · $2.8B

Quality 78: wide operating margins and F-Score 8/9. Momentum 74: estimates revised up and near its 52-week high. Value 66: cheap on P/E and below book value.

Yield —P/E 12.4
98
Score
78
Q
66
V
74
M
Full House
4
RIGL
Rigel Pharmaceuticals, Inc.
United States · $899.1M

Quality 83: high return on equity and strong free cash flow. Value 73: cheap on P/E and cheap on free cash flow. Momentum 63: above its moving averages and outperforming the market over 6 months.

Yield —P/E 2.5
98
Score
83
Q
73
V
63
M
Full HouseDir. sell $160K
5
BSLN.SW
Basilea Pharmaceutica AG
Switzerland · $1B

Momentum 81: estimates revised up and near its 52-week high. Quality 79: strong free cash flow and high return on equity. Value 51: far above book value.

Yield —P/E 17.7
97
Score
79
Q
51
V
81
M
Full House
6
EXEL
Exelixis, Inc.
United States · $16B

Quality 89: strong free cash flow and high return on equity. Momentum 76: near its 52-week high and above its moving averages. Value 43: far above book value.

Yield —P/E 20.8
96
Score
89
Q
43
V
76
M
Premium GrowerDir. sell $7.1MDeep dive →
7
AUPH
Aurinia Pharmaceuticals Inc.
Canada · $2.2B

Quality 84: high return on equity and wide operating margins. Momentum 61: estimates revised up and near its 52-week high. Value 60: cheap on P/E.

Yield —P/E 7.2
96
Score
84
Q
60
V
61
M
Full HouseDir. buy $12.5MDir. sell $546K
8
NRIX
Nurix Therapeutics, Inc.
United States · $2.8B

Quality 85: wide operating margins and strong free cash flow. Value 80: cheap on EV/EBITDA and cheap on P/E. Momentum 39: estimates cut.

Yield —P/E 6.3
95
Score
85
Q
80
V
39
M
Unloved QualityDir. sell $3.6M
9
CRMD
CorMedix Inc.
United States · $611.9M

Value 88: cheap on P/E and cheap on EV/EBITDA. Quality 81: high return on equity and strong free cash flow. Momentum 31: EPS deteriorating.

Yield —P/E 2.6
94
Score
81
Q
88
V
31
M
Unloved Quality
10
REGN
Regeneron Pharmaceuticals, Inc.
United States · $82.9B

Momentum 83: estimates revised up and near its 52-week high. Quality 71: wide operating margins and interest well covered. Value 45: little or no yield.

Yield 0.4%P/E 20.0
93
Score
71
Q
45
V
83
M
Premium GrowerDir. sell $52.4M
11
1177.HK
Sino Biopharmaceutical Limited
Hong Kong · $11.3B

Quality 72: wide operating margins and strong free cash flow. Momentum 68: estimates revised up and EPS improving. Value 60: cheap on free cash flow and cheap on EV/EBITDA.

Yield 2.1%P/E 37.3
93
Score
72
Q
60
V
68
M
Full House
12
688578.SS
Shanghai Allist Pharmaceuticals Co., Ltd.
China · $5.9B

Quality 94: wide operating margins and ROIC in the top 5% of its sector. Value 55: cheap on P/E but far above book value. Momentum 51: estimates revised up but estimates cut.

Yield 1.4%P/E 13.5
93
Score
94
Q
55
V
51
M
Full HouseDir. sell $38K
13
ADMA
ADMA Biologics, Inc.
United States · $2.4B

Quality 82: ROIC in the top 5% of its sector and wide operating margins. Momentum 69: estimates revised up and outperforming the market over 6 months. Value 48: far above book value.

Yield —P/E 16.5
93
Score
82
Q
48
V
69
M
Premium GrowerDir. buy $51KDir. sell $1.8M
14
PBYI
Puma Biotechnology, Inc.
United States · $568.9M

Quality 83: high gross profitability and strong free cash flow. Value 63: cheap on free cash flow and cheap on EV/EBITDA. Momentum 52: above its moving averages but EPS deteriorating.

Yield —P/E 17.9
93
Score
83
Q
63
V
52
M
Full HouseDir. sell $1.7M
15
1530.HK
3SBio Inc.
China · $4.4B

Quality 89: strong free cash flow and ROIC in the top 5% of its sector. Value 88: cheap on P/E and cheap on EV/EBITDA. Momentum 20: EPS deteriorating.

Yield 1.6%P/E 4.1
92
Score
89
Q
88
V
20
M
Unloved QualityDir. buy $2.0M
16
096530.KQ
Seegene, Inc.
South Korea · $1.2B

Quality 71: F-Score 8/9 and strong free cash flow. Value 66: cheap on EV/EBITDA and a high yield. Momentum 57: above its moving averages.

Yield 3.2%P/E 29.6
91
Score
71
Q
66
V
57
M
Full House
17
HALO
Halozyme Therapeutics, Inc.
United States · $14.3B

Quality 78: high return on equity and wide operating margins. Momentum 71: above its moving averages and outperforming the market over 6 months. Value 43: far above book value.

Yield —P/E 25.9
90
Score
78
Q
43
V
71
M
Premium GrowerDir. sell $26.4MDeep dive →
18
ZVRA
Zevra Therapeutics, Inc.
United States · $582.6M

Quality 88: ROIC in the top 5% of its sector and high return on equity. Value 62: cheap on P/E and cheap on free cash flow. Momentum 43: estimates cut.

Yield —P/E 9.5
90
Score
88
Q
62
V
43
M
Unloved QualityDir. sell $1.3M
19
INVA
Innoviva, Inc.
United States · $1.5B

Value 78: cheap on P/E and cheap on EV/EBITDA. Quality 71: wide operating margins and a liquid balance sheet. Momentum 42: EPS deteriorating.

Yield —P/E 8.1
89
Score
71
Q
78
V
42
M
Unloved QualityDeep dive →
20
688336.SS
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
China · $4.5B

Quality 95: strong free cash flow and low debt. Value 65: cheap on P/E and cheap on free cash flow. Momentum 29: EPS deteriorating.

Yield 0.9%P/E 9.7
88
Score
95
Q
65
V
29
M
Unloved Quality
21
2142.HK
HBM Holdings Limited
China · $1.1B

Quality 80: wide operating margins and ROIC in the top 5% of its sector. Value 55: cheap on P/E. Momentum 53: estimates revised up but EPS deteriorating.

Yield —P/E 12.1
87
Score
80
Q
55
V
53
M
Full House
22
UCB.BR
UCB SA
Belgium · $58.3B

Momentum 76: near its 52-week high and estimates revised up. Quality 75: F-Score 8/9 and wide operating margins. Value 36: little or no yield.

Yield 0.5%P/E 25.7
86
Score
75
Q
36
V
76
M
Premium GrowerDir. buy $176K
23
QTTB
Q32 Bio Inc.
United States · $257.5M

Quality 89: a liquid balance sheet and ROIC in the top 5% of its sector. Momentum 49: outperforming the market over 6 months but well off its 52-week high. Value 48: cheap on EV/EBITDA but far above book value; P/FCF excluded.

Yield —P/E —
86
Score
89
Q
48
V
49
M
Fallen FavouriteDir. buy $15MDir. sell $320K
24
ALEC
Alector, Inc.
United States · $204.3M

Value 74: cheap on P/E and cheap on EV/EBITDA; P/FCF excluded. Momentum 60: estimates revised up and near its 52-week high. Quality 52: wide operating margins but a weak F-Score 1/8.

Yield —P/E 6.2
86
Score
52
Q
74
V
60
M
Full HouseDir. sell $524K
25
INCY
Incyte Corporation
United States · $23.5B

Quality 82: wide operating margins and interest well covered. Momentum 64: EPS improving and near its 52-week high. Value 38: expensive on P/E.

Yield —P/E 61.0
85
Score
82
Q
38
V
64
M
Premium GrowerDir. sell $48.9M

Ranked by MoatMap Score, the 0 to 100 score of Quality, Value and Momentum, among companies worth $200M or more that trade $1M or more a day, one line per company. Director dealings are director purchases and sales filed in the last 180 days, where MoatMap carries the market's filings.